Cite
HARVARD Citation
Ruff, C. et al. (2021). LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, thrombosis, and vascular biology. 41 (12), pp. 3005-3014. [Online].